ATTIVITA' EDITORIALE
PUBBLICAZIONI
BANDO STUDENTI
|
|
PROF. G.E.RUSSO
Principali pubblicazioni degli ultimi anni
Prof. G.E. RUSSO
Efficacy of recombinant erythropoietin on the quality of life in patients over 60 years of age undergoing hemodialysis
RUSSO GE, GIUSTI S, VITALIANO E, CARAMIELLO MS, MAURICI M, DE MARCO CM, PENNACCHIA M, D'AURIA F, BONELLO M, BRUNO C, MARIGLIANO V.
We followed for a period of six months, 54 patients of over 60 years old, submitted to hemodialitic treatment. We gave human recombinant erythropoietin, average dosage 50 UI/Kg subcutaneously on alternative days, folic acid and iron supplements together with a proteic supply of 1.2 g/Kg/die (35 Kcal/Kg). The medullary response has been monitored with hematochemical tests; blood pressure and nutritional conditions have been evaluated. Furthermore, the patients were given a questionnaire to evaluate their quality of life. At the end of the follow up, 50 patients responded positively to therapy. These patients showed an increase of RBC (from 2,789,780 +/- 259,310 to 3,313,110 +/- 472,780 p < 0.001) of HCT (from 21.86% +/- 2.16% to 27.18 +/- 2.74% p < 0.0001) and of Hb (from 7.72 +/- 1.12 g/dl to 9.28 +/- 0.98 g/dl p < 0.006). Total protein and albumin increased too. Furthermore they showed a progressive increase of "performance status". Our results confirm efficacy of erythropoietin in the treatment of anemia in elderly hemodialized patients.
Clin Ter 1997 Mar;148(3):89-93
Pyelonephritis caused by mesalazine.
RUSSO GE, BAUCO B, BOSCO M, BONELLO M, BISCIGLIA MF, DE PAOLA A, VILLATICO CAMPBELL S, FAVA D, VITALIANO E
1. 2. Nephron 2000 Oct;86(2):228-9
Plasmapheresis combined with pharmacology in the treatment of lupus nephritis: a new therapeutic protocol
RUSSO GE, BONELLO M, VITALIANO E, BOSCO M, MARESCA L, DE PAOLA A, TEDALDI M, BISCIGLIA MF, BAUCO B.
Systemic Lupus Erythematosus (SLE) is a pathology of unknown cause, characterized by tissue and cellular damage, secondary to production of autoantibodies and to deposition of immunocomplexes. Lupus nephritis is one of the most common complications of SLE. Our purpose is to propose a therapeutic protocol for patients suffering from Lupus nephritis. This consists of Plasmapheresis associated with pharmacological therapy so that dosage of immunosuppressors can be reduced and consequently also the side effects of the pharmacological therapy.
Clin Ter 2000 Jan-Feb;151(1):9-13
Nephrotic syndrome and plasmapheresis.
RUSSO GE, BONELLO M, BAUCO B, BOSCO M, TEDALDI M, BISCIGLIA MF, VITALIANO E, RUSSO R, DEPAOLA A.
We studied 15 patients suffering from nephrotic syndrome (NS) in bioptically-accertained primary and secondary glomerulopathies responding poorly to the common pharmacological treatment. They were monitored for one year by assessing their immunological and kidney functionality parameters, especially proteinuria. The patients underwent 3 apheretic sittings using the cascade double-filtration technique. After the third apheretic sitting the patients received metilprednisolone 300 mg/m2. This therapy was repeated every month for 6 months. At the end of the apheretic cycle it was shown that all patients had responded well to the therapy with a dramatic decrease in proteinuria, maintenance and/or recuperation of kidney functionality and improvement of lipidic asset; these data remained unchanged over time. Considering our preliminary results, we believe that therapeutic apheresis has a precise function in refractory nephrotic syndrome and, in particular, we propose the use of the cascade double-filtration technique.
Int J Artif Organs 2000 Feb;23(2):111-3
The role of hypoxic stop-flow perfusion and high dose chemotherapy in the treatment of regionally advanced colorectal cancer.
DI GIORGIO A, FRANCHI F, DI SERI M, LACAVA V, CAROLI S, RUSSO GE, BORZOMATI V, AL MANSOUR M.
The primary or secondary forms of colorectal cancers involving local structures or spreading in the abdomen or pelvic area without extra-regional metastases are identified as regionally advanced colorectal cancers (RACRC). They are unresectable and thus radiotherapy and chemotherapy are the fundamental treatment methods. However, these regimens have failed to check the diffusion of tumor satisfactorily in most forms of RACRC. The abdominal and pelvic regions can be isolated from corporal circulation by temporary occlusion of the aorta and cava and perfused with high doses of chemotherapeutic drugs. The hypoxic abdominal or pelvic stop-flow method for delivering high-dose antiblastic agents to these body districts to avoid toxicity by chemofiltration has been suggested. This study examines the possibility of using this method to treat various forms of RACRC.
Chemother 1997 Dec;9(6):436-41
Plasmapheresis and mushroom poisoning:report of a case of Amanita phalloides poisoning
RUSSO GE, GIUSTI S, MAURICI M, BOSCO M, VITALIANO E, CARAMIELLO MS, BAUCO B, DE MARCO CM, MARIGLIANO V.
A case of amanita phalloides which presented a typical picture of phalloides intossication has been treated at our Centre. The patient was submitted to four treatments of plasmaexchange (Plasmafiltration), exchanging from 70 to 80% of the plasmatic volume and using substitutive liquids 4% albumine and frozen plasma, using as filter Plasmaflo Asahi OP-O5 (1) and Plasmapheresis equipment SIFRA mod. 914. Already after the first treatment there was an improvement of the general condition with a stabilization of the renal and hepatic parameters at the end of the cycle.
Clin Ter 1997 May-Jun;148(5-6):277-80
Comparative study of the modification of arterial pressure in adult and aged subjects treated with hemofiltration. Preliminary results
RUSSO GE, GIUSTI S, VITALIANO E, MAURICI M, DE MARCO CM, CARAMIELLO MS, BONELLO M, PENNACCHIA M, BRUNO C, SCUTERI A, MARIGLIANO V.
Haemodynamics modifications in 49 patients divided in two groups consisting of 21 young people (average age 43 +/- 12 yrs.) and 28 elderly people (average age 72 +/- 7 yrs.) who have undergone at least three treatments with haemofiltration for congestive cardiac decompensation and chronic renal failure have been evaluated. Systolic and diastolic blood pressure and heart rate have been monitored for each patient in a length of time of iT, T30 min., T60 min., fT. The results show a statistically significant reduction of the systolic pressure during the time interval iT-T30 min. in subjects over 65, contrary to the control group. Such preliminary results can be justified by the haemodynamic modifications correlated to the elderly process. In any case the hypothesis cited by the authors need further testing even if confirming the indication of the dialytic treatment on patients over 65 through haemofiltration techniques.
Clin Ter 1997 May-Jun;148(5-6):225-8
Efficacy of recombinant erythropoietin on the quality of life in patients over 60 years of age undergoing hemodialysis
RUSSO GE, GIUSTI S, VITALIANO E, CARAMIELLO MS, MAURICI M, DE MARCO CM, PENNACCHIA M, D'AURIA F, BONELLO M, BRUNO C, MARIGLIANO V.
We followed for a period of six months, 54 patients of over 60 years old, submitted to hemodialitic treatment. We gave human recombinant erythropoietin, average dosage 50 UI/Kg subcutaneously on alternative days, folic acid and iron supplements together with a proteic supply of 1.2 g/Kg/die (35 Kcal/Kg). The medullary response has been monitored with hematochemical tests; blood pressure and nutritional conditions have been evaluated. Furthermore, the patients were given a questionnaire to evaluate their quality of life. At the end of the follow up, 50 patients responded positively to therapy. These patients showed an increase of RBC (from 2,789,780 +/- 259,310 to 3,313,110 +/- 472,780 p < 0.001) of HCT (from 21.86% +/- 2.16% to 27.18 +/- 2.74% p < 0.0001) and of Hb (from 7.72 +/- 1.12 g/dl to 9.28 +/- 0.98 g/dl p < 0.006). Total protein and albumin increased too. Furthermore they showed a progressive increase of "performance status". Our results confirm efficacy of erythropoietin in the treatment of anemia in elderly hemodialized patients.
Clin Ter 1997 Mar;148(3):89-93
Haemorheological changes in mixed cryoglobulinaemia during apheresis treatment.
RUSSO GE, CARAMIELLO MS, VITALIANO E, DE MARCO CM, PENNACCHIA M, GIUSTI S, VANNINI F, MANNINI L, AVANZI G.
Thirty-four patients affected by mixed cryoglobulinaemia have been submitted to treatment by apheresis (plasma exchange or double cascade filtration). The authors have monitored clinical, laboratory and, above all, haemorheological changes following therapy. The final results have shown mainly a reduction of plasma viscosity and consequently an improvement of the haemorheology of the affected organs. In conclusion, apheresis may be considered a successful therapy in patients with severe renal or neurological diseases due to mixed cryoglobulinaemia.
Transfus Sci 1996 Dec;17(4):499-503
Reinfusion ascites therapy: considerations after a year's experience
RUSSO GE, CARAMIELLO MS, VITALIANO E, FAGIOLO M, PAZIENZA M, TESTORIO M, CARMENINI G, SAGLIASCHI G.
Ascites often appears as a complication of several illnesses. The therapy is essentially based on the use of low-sodium diet, plasma or albumin infusion, diuretics and low-dosed ACE-inhibitors. To use the simple paracentesis or special techniques as Rhodiascit or Lee Veen Shunt means not to resolve definitively the problem and sometimes to cause undesirable complications. The authors present a new therapeutic tactics that joins the use of technique of double filtration of ascitic fluid and reinfusion of concentrated proteins (DFAF) with the injection in the peritoneal cavity of beta-interferon and the venous infusion of ATIII. Twenty patients affected by hepatic cirrhosis with the presence of ascitic fluid not treatable with the usual therapy have been subjected to this treatment. All the patients showed an immediate improvement of the clinical situation. After one year of observation, we describe our results. Twelve patients needed a further treatment with the DFAF technique, two patients died for the original pathology and six patients just needed an adjustment of pharmacologic therapy.
Riv Eur Sci Med Farmacol 1994 May-Aug;16(3-4):79-83
Biocompatibility in hemapheresis: new materials.
RUSSO GE, FAGIOLO M, VITALIANO E, CARAMIELLO MS.
The development of new technologies implying the use of semidialytic synthetic membranes in therapeutic apheresis, lays stress also on the problem of biocompatibility. The first alterations of plasma proteins and of the immune system are observable 15 minutes after the beginning of the apheretic session. This may suggest that the acute clinical reactions observed during apheresis are related to biocompatibility. However, the first chronic side effects, comparable to those observed in hemodialysis, do not occur before 10-20 sessions. It is known, in fact, that even when inactive materials, such as the last generation membrane, are used, plasma exchange affects the immune system and may determine plasma protein alterations (protein film, erythrocytic damage, ADP release, beginning of the coagulation process, complement consumption). The whole system or the type of membrane, the involucre, the potting glue and the lines affect the interactions. The contact of blood with a foreign surface initiates a number of local reaction, with subsequent reactivity of the organism. The activation of the complement system, coagulative system, fibrinolytic system and callicrein-kinin system is therefore responsible for the cell functional modifications. It is necessary to underline the role of the membrane surface used, in that the activation of the complement system, of the gathering of platelets and of the cell activity modification all increase with the increase in surface. Biocompatibility may be affected not only by the membranes, but also by the substitution fluids and by the anticoagulant used.
Int J Artif Organs 1993 Dec;16 Suppl 5:214-6
Nonspecific cholestatic syndrome in liver transplantation: successful symptomatic treatment by plasma exchange.
BRUZZONE P, ALFANI D, BERLOCO P, IAPPELLI M, ROSSI M, CASCIARO G, CARICATO M, CARAMIELLO MS, FAGIOLO M, RUSSO GE, ET AL.
Transplant Proc 1993 Apr;25(2):1753-4
Pruritus in chronic uremic patients in periodic hemodialysis. Treatment with terfenadine (an antagonist of histamine H1 receptors)
RUSSO GE, SPAZIANI M, GUIDOTTI C, SCARPELLINI MG, LERI O, BONINI S, CRISCIOTTI C, CARMENINI G.
Minerva Urol Nefrol 1986 Oct-Dec;38(4):443-7
Indications for treatment of nephrovascular hypertension
Russo GE, Nuzzolo L, Di Maio F, Kamaris C, Capobianco L.
Clin Ter 1981 Jul 31;98(2):161-9
|